RSC Advances

Journal Name

ARTICLE

Positive and negative allosteric effects for thiacalix[4]arene-based receptors bearing urea and crown–ether moieties†

Hirotsugu Tomiyasu,[a] Jiang-Lin Zhao,[a] Xin–Long Ni,[b] Xi Zeng,[b] Mark R. J. Elsegood,[c] Beth Jones,[c] Carl Redshaw,[d] Simon J. Teat[e] and Takehiko Yamato[a*]

Heteroditopic receptors ($4_{a\sim e}$) based on a thiacalix[4]arene in the 1,3-*alternate* conformation, which have two urea moieties linking various phenyl groups substituted with either electron-donating or -withdrawing groups at their *m*-, or *p*-positions with a crown-ether moiety at the opposite side of thiacalix[4]arene cavity, have been synthesized. The two examples with *p*-CH$_3$- (4_b) and *p*-NO$_2$-substituted (4_e) (phenyl groups have been characterized by X-ray crystallography. The binding property of receptors 4_e was investigated by means of ^{1}H NMR spectroscopic and absorption titration experiments in CHCl$_3$–DMSO (10:1, v/v) solution in the presence of K$^+$ ion and various anions. Interestingly, it was found that receptor 4_e, which possesses two *p*-nitrophenyl ureido moieties, can complex most efficiently in the urea cavity or the crown-ether moiety; and the plausible allosteric effect of receptor 4_e was also studied.

Introduction

The use of calix[*n*]arenes[1] as building blocks for receptors capable of the highly selective recognition of cations, anions or neutral molecules has received considerable attention in the field of supramolecular chemistry. Among the various kinds of calix[*n*]arenes available, thiacalix[4]arenes[2, 3] are proving to be competent scaffolds and are finding wide use, for example as chemosensors, as well as in catalysis because of their favourable conformational properties, easy functionalization and emerging metal coordination chemistry. Several kinds of systems based on thiacalix[4]arenes are suitable for allosteric regulation[4] of host-guest interactions with metal cations, and these contribute greatly to organic processes in biological systems. Anions also play an important role in the biological process, and are closely related with biological systems such as DNA and enzyme substrates. The development and the investigation of anion selective sensors[5] have attracted considerable interest. However, it is more difficult to accomplish compared with metal cation sensors because anions can possess structures of different shapes,[6] typically spherical (F⁻, Cl⁻, Br⁻, I⁻), Y–shaped (AcO⁻, PhCOO⁻) or tetrahedral (H$_2$PO$_4^-$). In recent years, anion receptors based on calix[*n*]arenes has become an active research topic. Calix[*n*]arene urea derivatives are efficient for anion recognition given the hydrogen-bonding interaction between anions and N–H protons which can occur.

Colorimetric chemosensors[7, 8] have also attracted attention due to some desirable features such as easy detection by the naked eye, construction of simple low-cost devices and so on. Many colorimetric anion receptors containing a variety of chromogenic signaling units such as indole, imidazolium, benzenediimide, 4-nitrophenylazo, diazo and anthraquinone groups have been developed. Furthermore, numerous colorimetric anion sensors utilizing a variety of structural scaffolds, which contain urea groups, have been investigated and proved to be efficient naked–eye detectors for various anions. However, there are a few reports on the development of colorimetric chemosensors based calix[4]arene type scaffolds.[8l,p]

Lhoták[9] and co-workers have reported anion receptors based on either an upper rim substituted calix[4]arene or thiacalix[4]- arene, which contains two *p*-nitrophenyl or *p*-tolyl ureido moieties.[9a~c,h] These anion receptors exhibited effective recognition abilities towards selected anions in common organic solvents. Moreover, Kumar[10] and co-workers reported an anion receptor bearing a calix[4]arene in the 1,3-*alternate* conformation, which contains two *p*-nitrophenyl moieties.[10g] This compound exhibited strong binding and good selectivity for Cl⁻ ion due to the formation of strong hydrogen bonds between the Cl⁻ ion and N–H protons in common organic solvents. However, investigations concerning the appearance of an allosteric effect in analogues based on the interaction of thiacalix[4]arene and alkali metal cations and anions has not yet been reported.

Herein, we have independently designed a heterodimeric system[11] based on a thiacalix[4]arene having two different side arms, *viz* two ureas moieties linking various phenyl groups

bearing either electron-donating or -withdrawing groups at their *m*-, or *p*-positions. The calixarene also has a crown ether moiety at the opposite side of the thiacalix[4]arene cavity. We herein put forward the hypothesis (and then demonstrate) that the heterodimeric system, which is controlled by the complexation of the opposing side arms with anions and K$^+$ ion, exhibits effective positive and negative allosteric effects.

Results and discussions

Synthesis

The *O*-alkylation of *distal*-**1** was carried out with 1.5 equivalents of tetraethyleneglycol ditosylate in the presence of an equivalent of K$_2$CO$_3$ according to the reported procedure, and afforded the desired 1,3-*alternate*-**2** in 83 % yield.[12] The hydrazinolysis of 1,3-*alternate*-**2** was carried out with a large excess of hydrazine hydrate, and afforded the desired 1,3-*alternate*-**3** in 86 %. The condensation of 1,3-*alternate*-**3** with 2.2 equivalents of the appropriate isocyanate in THF furnished the receptors **4$_{a~e}$** in good to excellent yields (Scheme 1). In general, the ^{1}H NMR spectrum of receptors **4$_{a~e}$** in CDCl$_3$–DMSO (10:1, v/v) exhibited the characteristics of a 1,3-*alternate* canformation such as two singlets (18H each) for the *tert*-butyl protons, one singlet (4H) for O*CH$_2$*CO protons, two singlets (4H each) for aromatic protons and two singlets (2H each) for four urea NH protons.

Scheme 1 Synthesis of receptors 1,3-*alternate*-**4$_{a~e}$**.

The molecular structures of receptors **4$_b$** and **4$_e$** were also verified by X-ray crystallographic analysis (Fig. 1 and S15-S16). Receptors **4$_b$** and **4$_e$** were recrystallized from a mixture of CHCl$_3$–CH$_3$CN (1:1, v/v) by slow evaporation. These results indicate that receptors **4$_b$** and **4$_e$** adopt the 1,3-*alternate* conformation in the solid state, respectively. There are two thiacalixarenes, one water molecule and three chloroform molecules in the asymmetric unit. Interestingly, it was found that two urea groups approach each other and are oriented in parallel due to the existence of dual intramolecular hydrogen bonding (in case of receptor **4$_e$**, for the molecule shown: N(14)–H(14)···O(21) 2.37(2); N(15)–H(15)···

**Fig. 1** X–ray crystal structure of receptor **4e**. H–bonds shown as dashed lines. One of two similar molecules in the asymmetric unit is shown in two orientations rotated by approx. 90°. H atoms not involved in H-bonding, minor disorder components, and solvent of crystallization are omitted for clarity.

Table 1 Association constants[a] of receptor $4_{a\sim e}$ with Cl^- ions[b]

Host	4_a	4_b	4_c	4_d	4_e
R	H	p-CH$_3$	p-CF$_3$	3,5-(CF$_3$)$_2$	p-NO$_2$
K_a [M^{-1}]	6816±545	3021±242	12813±1025	6945±625	34411±2400

[a] Measured in CDCl$_3$–DMSO (10:1, v/v) at 298 K by the ^{1}H NMR titration method using the chemical-shift change of the NH$_a$ proton (Fig. S17–S22); host concentration was 4.0×10^{-3} M. [b] Guests used: Bu$_4$NCl.

O(21) 2.05(2) Å; for the second molecule: N(2)–H(2)$\cdots$O(10) 2.37, N(3)–H(3)$\cdots$O(10) 1.94(2) Å) (Fig. 1 and S16). Moreover, the thiacalix[4]arene–monocrown–5 has a three-dimentional cavity and is large enough to accommodate the metal cation. The association constants (K_a values) between the receptors $4_{a\sim e}$ and Cl^- ion were determined by ^{1}H NMR spectroscopic titration experiments, respectively (Table 1). These results suggest that the association constants depend on the electron-donating/ withdrawing groups located at the m-, or p-positions. In the presence of the electron-withdrawing groups, such as CF$_3$ (receptors 4_c and 4_d) and NO$_2$ (receptor 4_e), the K_a values were greater than that for the unsubstituted receptor (receptor 4_a). In contrast, in the case of receptor 4_b, possessing the electron-donating Me group, there was a general decrease in the K_a value upon complexation with Cl^- ion in comparison with the unsubstituted receptor 4_a. Therefore, the introduction of electron–withdrawing groups at the m-, or p-positions appears to increase the acidity of the urea protons, and hence enhance the anion-binding ability through hydrogen-bonding interactions. The K_a value of receptor 4_e with the electron-withdrawing NO$_2$ group at the p-position was the best out of all the K_a values measured for receptors $4_{a\sim e}$ and Cl^- ion. Interestingly, it was found that the K_a value of receptor 4_c with the electron-withdrawing CF$_3$ group at the p-position was greater than that of receptor 4_d with the electron–withdrawing CF$_3$ group at the m-position. This result indicates that electron–withdrawing groups located at the p-position can significantly influence the acidity of the urea protons by conjugating with the phenyl groups. From the above, it is clear that receptor 4_e with the electron-withdrawing NO$_2$ group at the p-position has the most effective recognition ability toward selected anions. Given this, further complexation studies of receptor 4_e (2.5 µM) exhibits an absorption band at 310 nm in the UV spectrum in the absence of anions. Upon addition of Cl^- ion (0–50 µM) to the solution of receptor 4_e, Fig. 2 reveals a gradual decrease in the absorption of the band at 310 nm with a simultaneous increase in the absorption at 340 nm. Meanwhile, a clear isosbestic

Fig. 2 UV–vis absorption spectra of receptor 4_e (2.5 µM) upon the addition of Bu$_4$NCl (0–50 µM) in CH$_2$Cl$_2$–DMSO (10:1, v/v).

**Fig. 3** Binding mode of receptor 4_e upon complexation with Cl^- ions.

point was observed at 322 nm for the receptor 4_e. A Job's plot binding between the receptor 4_e and Cl^- ion reveals a 1:1 stoichiometry (Fig. S25), whilst the association constant (K_a value) for the complexation with Cl^- ion by receptor 4_e was determined to be 34152 M^{-1} by UV–vis titration experiments in CHCl$_3$–DMSO (10:1, v/v) (Fig. S24, S27–S31). Moreover, the concentration

Table 2 Association constants[a] of receptor 4_e with various anions[b]

Anion	F$^-$	Cl$^-$	Br$^-$	I$^-$	AcO$^-$	PhCO$_2^-$	H$_2$PO$_4^-$
Shape	Spherical	Spherical	Spherical	Spherical	Y-shape	Y-shape	Tetrahedral
K_a [M^{-1}]	128775±10302	34152±2732	7296±584	4540±363	107298±8584	106743±8539	108687±8695

[a] Measured in CH$_2$Cl$_2$–DMSO (10:1, v/v) at 298 K by UV–vis titration method (Fig. 2, 4, S24 and S27–S31); host concentration was 2.5 µM.
[b] Guests used: tetrabutylammonium salt.

Fig. 4 UV–vis absorption spectra of receptor 4_e (2.5 μM) upon the addition of Bu₄NF (0–50 μM) in CH₂Cl₂–DMSO (10:1, v/v).

**Fig. 5** Partial ¹H NMR spectra of receptor 4_e/guest (H/G = 1:1); free receptor 4_e and in the presence of 1 equiv. of Bu₄NX (X = F, Cl, Br, I, AcO, PhCOO, H₂PO₄), respectively. Host concentration was 2.5 μM. Solvent: CDCl₃–DMSO (10:1, v/v). 300 MHz at 298 K. *Denotes the solvent peak.

Fig. 6 Proposed positive allosteric behaviour of receptor 4_e with Br⁻ and K⁺ ions. Partial ¹H NMR spectra of 4_e/guest (H/G = 1:1); a) free 4_e; b) $4_e \supset KSO_3CF_3$; c) Bu₄NBr ⊂ [$4_e \supset K^+$]; d) $4_e \supset$ Bu₄NBr. Solvent: CDCl₃–DMSO (10:1, v/v). 300 MHz at 298 K. *Denotes the solvent peak.

Fig. 7 Proposed negative allosteric behaviour of 4_e with Cl⁻ and K⁺ ions. Partial ¹H NMR spectra of 4_e/guest (H/G = 1:1); a) free 4_e; b) $4_e \supset KSO_3CF_3$; c) Bu₄NCl ⊂ [$4_e \supset K^+$]; d) $4_e \supset$ Bu₄NCl. Solvent: CDCl₃–DMSO (10:1, v/v). 300 MHz at 298 K. *Denotes the solvent peak.

dependence of the ¹H NMR chemical shifts of the ureido protons in receptor 4_e was not observed (Fig. S23). This result suggests that receptor 4_e has a strong intramolecular hydrogen bond between the two ureas linking the p-nitrophenyl moieties. These results strongly suggested that Cl⁻ ion recognition by receptor 4_e was via a hydrogen-bonding interaction between the Cl⁻ ion and N–H protons as shown in Fig. 3. Similarly, the UV–vis titration experiments of receptor 4_e with other various anions besides Cl⁻ ion were carried out, and the K_a values are summarized in Table 2. As a result, it was found that receptor 4_e exhibited high selectivity towards F⁻ ion amongst all of the anions tested, and was capable of complexing with all of the anions tested, irrespective of their shape. Interestingly, the color of the receptor 4_e solution changed from colorless to dark

yellow upon addition of F$^-$ ion (5 equivalents), and this could be easily observed by the naked eye. Upon the addition of F$^-$ ions (0–50 µM) to the solution of the receptor 4_e, the absorption peak at 342 nm gradually moved to a longer wavelength, finally reaching a maximum value at 360 nm (Fig. 4 and S26). This result suggests that the quinoid structure was formed by the deprotonation of urea NH groups in the *p*–nitrophenyl ureido moiety. Moreover, the addition of F$^-$, AcO$^-$, PhCOO$^-$ or H$_2$PO$_4^-$ (1 equivalent) to solutions of receptor 4_e in CHCl$_3$–DMSO (10:1, v/v) during the ^{1}H NMR titration experiments resulted in the disappearance of the urea proton signals, NH$_a$ and NH$_b$ (Fig. 5). These results indicate that strong interactions between these anions and the urea NH groups in the receptor 4_e occur and that the kinetics of these anion exchanges is on the NMR time scale. On the other hand, ^{1}H NMR spectroscopic and UV–vis titration experiments of receptor 4_e with K$^+$ ion at the crown-ether moiety were also carried out (Fig. S32–S33). When only K$^+$ ion (1 equivalent) were added, not only the downfield shift of the crown-ether bridge protons was observed, but also all the NH protons in ^{1}H NMR titration experiments (Fig. 6b and 7b). It was found that a Job's plot binding between receptor 4_e and K$^+$ ion exhibited a 1:1 stoichiometry and that the K_a value for the complexation with K$^+$ ion was determined to be 28536 ($\pm$ 1998) M^{-1} by UV–vis titration experiments in CH$_2$Cl$_2$–DMSO (10:1,v/v) (Fig. S34–35). These results suggest that the crown-5 ring of receptor 4_e binds K$^+$ ion. To seek more detailed information about the presence of an effective positive or negative allosteric effect between receptor 4_e·K$^+$ and Br$^-$ or Cl$^-$ ions, ^{1}H NMR spectroscopic and UV–vis titration experiments in CHCl$_3$–DMSO (10:1, v/v) (Fig. S36) were carried. Fig. 6 reveals that when Br$^-$ ion were added to the solution of [$4_e{\supset}$KSO$_3$CF$_3$] (Fig. 6c), the addition induces a downfield shift of 0.42 ppm (δ = 9.09 to 9.51 ppm) for the NH$_a$ protons, and upfield shifts of 0.85 ppm (δ = 8.95 to 8.10 ppm) for the NH$_b$ protons and of 0.29 ppm (δ = 8.10 to 7.81 ppm) for the NH$_c$ protons, while the chemical shifts for the crown–ether bridge protons did not change. These results suggested the formation of a heteroditopic dinuclear complex of the type Br$^-$ $\subset$ [$4_e{\supset}$K$^+$] (Fig. 6c), and we propose a positive allosteric effect of receptor 4_e towards Br$^-$ ion in the presence of K$^+$ ion by an ion–pair electrostatic interaction and a conformational change of the flexible thiacalix[4]arene cavity as shown in Fig. 6. On the other hand, Fig. 7 shows that when Cl$^-$ ion were added to the solution of [$4_e{\supset}$KSO$_3$CF$_3$] (Fig. 7c), this addition induces a downfield shift of 1.11 ppm (δ = 9.09 to 10.2 ppm) for the NH$_a$ protons and 0.04 ppm (δ = 8.10 to 8.14 ppm) for the NH$_c$ protons, and an upfield shift of 0.37 ppm (δ = 8.95 to 8.58 ppm) for the NH$_b$ protons, together with upfield shifts for the crown-ether bridge protons. Interestingly, when Cl$^-$ ion were added to the solution of [$4_e{\supset}$KSO$_3$CF$_3$] (Fig. 7c), the chemical shifts for the crown–ether bridge protons most closely matched the chemical shifts for the free crown-ether bridge protons (Fig. 7c and 7d). These results suggested that the two urea groups in two *p*–nitrophenyl ureido moieties of receptor 4_e·K$^+$ bind the Cl$^-$ ion by an ion–pair electrostatic interaction and a conformational change of the flexible thiacalix[4]arene cavity, which induces the decomplexation of the K$^+$ ion from the crown-5 ring of receptor 4_e because the Cl$^-$ ion has a smaller ionic radius and therefore an increase in basicity in comparison with the Br$^-$ ion, and a negative allosteric effect of

receptor 4_e to Cl$^-$ ion in the presence of K$^+$ ion as shown in Fig. 7 is proposed.

Conclusion

In summary, a new family of heteroditopic receptors ($4_{a\sim e}$) based on a thiacalix[4]arene in the 1,3-*alternate* conformation, which has two ureas moieties bearing various phenyl groups substituted with either electron-donating or -withdrawing groups at their *m*-, or *p*-positions, as well as a crown-ether moiety at the opposite side of thiacalix[4]arene cavity, has been synthesized. By using ^{1}H NMR spectroscopic and UV–vis titration experiments, receptor 4_e possessing an electron–withdrawing NO$_2$ group at the *p*-position has the most effective recognition ability towards the selected anions. The binding of K$^+$ ions and various anions at the crown-**5** ring moiety and the two urea NH groups in two *p*-nitrophenyl ureido moieties, respectively, was investigated. The results indicated the complexation mode, and it found that receptor 4_e was able to bind all of the anions tested, irrespective of their shape. Receptor 4_e exhibited high selectivity towards F$^-$ ion amongst all of the anions tested and indicated that this receptor might be a promising candidate as a colorimetric chemosensor. The appearance of positive and negative allosteric effects in receptor 4_e was also investigated by ^{1}H NMR and UV–vis titration experiments. Interestingly, the formation of a heteroditopic dinuclear complex of receptor 4_e with Br$^-$ and K$^+$ ions by a positive allosteric effect could be observed. On the other hand, the fact that two urea NH groups in two *p*-nitrophenyl ureido moieties of receptor 4_e·K$^+$ bind the Cl$^-$ ion, which then induces the decomplexation of the K$^+$ ion from the crown-5 ring, is indicative of a negative allosteric effect.

Experimental Section

General

All melting points were determined with Yanagimoto MP-S1. ^{1}H-NMR spectra were determined at 300 MHz with a Nippon Denshi JEOL FT-300 NMR spectrometer with SiMe$_4$ as an internal reference; J-values are given in Hz. UV spectra were measured by a Shimadzu 240 spectrophotometer. Mass spectra were obtained on a Nippon Denshi JMS-01SG-2 mass spectrometer at an ionization energy of 70 eV using a direct inlet system through GLC. Elemental analyses were performed by Yanaco MT-5.

Materials

Unless otherwise stated, all other reagents used were purchased from commercial sources and used without further purification. Compounds **1**[13] and **2**[12] were prepared following the reported procedures.

Synthesis of compound 3

Compound **2** (1.0 g, 0.95 mmol) was put into a round-bottom flask and ethanol (120 mL), THF (120 mL) and hydrazine hydrate (14 mL, large excess) were added and refluxed for 48

h. After cooling, the solvents and excess hydrazine were removed under reduced pressure to give the crude product as a white solid. The residue was triturated sequentially with water and methanol and the product collected by filtration. Compound **3** was obtained 0.84 g (86 %) as a white solid. M.p. 216–218 °C. IR: υ_{max} (KBr)/cm^{-1}: 3421, 2961, 1670, 1438, 1263, 1091, 1019 and 801. ^{1}H NMR (300 MHz, CDCl$_3$): δ = 1.25 (18H, s, *t*Bu× 2), 1.37 (18H, s, *t*Bu × 2), 3.00 (4H, t, *J* = 9.1 Hz, O*CH$_2$* × 2), 3.39 (4H, br, O*CH$_2$* × 2), 3.48 (4H, br, *NH$_2$* × 2), 3.60 (4H, broad s, O*CH$_2$* × 2), 3.96 (4H, t, *J* = 9.1 Hz, O*CH$_2$*× 2), 4.55 (4H, s, O*CH$_2$*CO × 2), 7.35 (4H, s, Ar–*H* × 2), 7.41 (4H, s, Ar–*H* × 2) and 7.54 (2H, s, N*H* × 2) ppm. ^{13}C NMR (100 MHz, CDCl$_3$): δ = 30.5 (CH$_3$), 33.5 (C(CH$_3$)$_3$), 64.9 (OCH$_2$), 67.4 (OCH$_2$), 69.2 (OCH$_2$), 70.5 (OCH$_2$), 72.6 (OCH$_2$), 126.2 (ArC), 126.4 (ArC), 126.5 (ArC), 126.7 (ArC), 146.5 (ArC), 146.7 (ArC), 153.6 (ArC), 155.4 (ArC) and 167.6 (CO) ppm. FABMS: *m/z*: 1023.38 (M$^+$). C$_{52}$H$_{70}$N$_4$O$_9$S$_4$ (1023.39): calcd C 61.03, H 6.89, N 5.47. Found: C 61.33, H 6.79, N 5.57.

Synthesis of receptor 4$_a$

To compound **3** (150 mg, 0.147 mmol) in THF (10 mL), was added phenyl isocyanate (38 mg, 0.320 mmol) and the mixture was stirred for at room temperature for 24 h under argon. The resulting precipitate was collected by filtration, washed with hexane to give receptor **4$_a$** as a white solid. Recrystallization from CHCl$_3$–CH$_3$CN (4:1) gave receptor **4$_a$** (154 mg, 83 %) as white solid. M.p. 202–205 °C. IR: υ_{max} (KBr)/cm^{-1}: 3270, 2956, 1674, 1547, 1442, 1263, 1221, 1153, 1091, 799 and 751. ^{1}H NMR (300 MHz, CDCl$_3$–DMSO, 10:1): δ = 1.25 (18H, s, *t*Bu × 2), 1.39 (18H, s, *t*Bu × 2), 2.97 (4H, t, *J* = 9.1 Hz, O*CH$_2$* × 2), 3.40 (4H, br, O*CH$_2$* × 2), 3.63 (4H, s, O*CH$_2$* × 2), 3.85 (4H, t, *J* = 9.1 Hz, O*CH$_2$* × 2), 4.59 (4H, s, O*CH$_2$*CO × 2), 6.95 (2H, t, *J* = 7.3 Hz, Phenyl–*H* × 2), 7.15 (4H, t, *J* = 7.6 Hz, Phenyl–*H* × 4), 7.31 (4H, d, *J* = 7.7 Hz, Phenyl–*H* × 2), 7.35 (4H, s, Ar–*H* × 4), 7.48 (4H, s, Ar–*H* × 4), 7.57 (2H, s, N*H* × 2), 8.10 (2H, s, N*H* × 2), 8.32 (2H, s, N*H* × 2) ppm. ^{13}C NMR (100 MHz, CDCl$_3$–DMSO, 10:1): δ = 29.9 (CH$_3$), 30.4 (CH$_3$), 33.5 (C(CH$_3$)$_3$), 33.5 (C(CH$_3$)$_3$), 64.9 (OCH$_2$), 67.5 (OCH$_2$), 69.0 (OCH$_2$), 70.6 (OCH$_2$), 72.6 (OCH$_2$), 118.4 (ArC), 120.4 (ArC), 121.8 (ArC), 125.6 (ArC), 126.1 (ArC), 126.3 (ArC), 127.1 (ArC), 127.5 (ArC), 128.0 (ArC), 128.2 (ArC), 137.3 (ArC), 146.4 (ArC), 147.5 (ArC), 153.7 (ArC), 154.0 (CO), 154.6 (ArC) and 167.5 (CO) ppm. FABMS: *m/z*: 1261.43 (M$^+$). C$_{66}$H$_{80}$N$_6$O$_{11}$S$_4$ (1260.48): calcd C 62.83, H 6.39, N 6.66. Found: C 62.59, H 6.23, N 6.45.

Synthesis of receptor 4$_b$

To compound **3** (150 mg, 0.147 mmol) in THF (10 mL), was added *p*–tolyl isocyanate (43 mg, 0.320 mmol) and the mixture was stirred for at room temperature for 24 h under argon. The resulting precipitate was collected by filtration, washed with EtOH to give receptor **4$_b$** as a white solid. Recrystallization from CHCl$_3$–CH$_3$CN (2:1) gave receptor **4$_b$** (163 mg, 86 %) as white solid. M.p. 205–207 °C. IR: υ_{max} (KBr)/cm^{-1}: 3283, 2955,

1678, 1547, 1444, 1266, 1207, 1151, 1089, 999 and 815. ^{1}H NMR (300 MHz, CDCl$_3$–DMSO, 10:1): δ = 1.27 (18H, s, *t*Bu × 2), 1.39 (18H, s, *t*Bu × 2), 2.28 (6H, s, *CH$_3$* × 2), 2.97 (4H, t, *J* = 9.1 Hz, O*CH$_2$* × 2), 3.40 (4H, br, O*CH$_2$* × 2), 3.63 (4H, s, O*CH$_2$* × 2), 3.85 (4H, t, *J* = 9.1 Hz, O*CH$_2$* × 2), 4.58 (4H, s, O*CH$_2$*CO × 2), 6.96 (4H, d, *J* = 7.7 Hz, Phenyl–*H* × 4), 7.16 (4H, d, *J* = 7.7 Hz, Phenyl–*H* × 4), 7.35 (4H, s, Ar–*H* × 4), 7.48 (4H, s, Ar–*H* × 4), 7.51 (2H, s, N*H* × 2), 8.10 (2H, s, N*H* × 2), 8.22 (2H, s, N*H* × 2) ppm. ^{13}C NMR (100 MHz, CDCl$_3$–DMSO, 10:1): δ = 20.7 (CH$_3$), 30.9 (CH$_3$), 31.4 (CH$_3$), 34.4 (C(CH$_3$)$_3$), 34.5 (C(CH$_3$)$_3$), 65.9 (OCH$_2$), 68.6 (OCH$_2$), 70.0 (OCH$_2$), 71.6 (OCH$_2$), 73.6 (OCH$_2$), 119.4 (ArC), 126.6 (ArC), 127.0 (ArC), 127.3 (ArC), 128.2 (ArC), 129.0 (ArC), 129.5 (ArC), 131.9 (ArC), 135.7 (ArC), 136.1 (ArC), 147.4 (ArC), 148.5 (ArC), 154.4 (ArC), 154.8 (ArC), 155.1 (CO), 155.5 (ArC) and 168.5 (CO) ppm. FABMS: *m/z*: 1289.46 (M$^+$). C$_{68}$H$_{84}$N$_6$O$_{11}$S$_4$ (1289.69): calcd C 63.33, H 6.56, N 6.52. Found: C 62.56, H 6.56, N 6.25.

Synthesis of receptor 4$_c$

To compound **3** (150 mg, 0.147 mmol) in THF (10 mL), was added *p*–trifluoromethylphenyl isocyanate (59 mg, 0.320 mmol) and the mixture was stirred for at room temperature for 24 h under argon. The resulting precipitate was collected by filtration, washed with EtOH to give receptor **4$_c$** as a white solid. Recrystallization from CHCl$_3$–CH$_3$CN (1:1) gave receptor **4$_c$** (164 mg, 80%) as white solid. M.p. 207–210 °C. IR: υ_{max} (KBr)/cm^{-1}: 3283, 2959, 1687, 1548, 1445, 1266, 1158, 1091, 1068 and 840. ^{1}H NMR (300 MHz, CDCl$_3$–DMSO, 10:1): δ = 1.27 (18H, s, *t*Bu × 2), 1.40 (18H, s, *t*Bu × 2), 2.97 (4H, t, *J* = 9.1 Hz, O*CH$_2$* × 2), 3.40 (4H, br, O*CH$_2$* × 2), 3.63 (4H, s, O*CH$_2$* × 2), 3.85 (4H, t, *J* = 9.1 Hz, O*CH$_2$* × 2), 4.61 (4H, s, O*CH$_2$*CO × 2), 7.36 (4H, s, Ar–*H* × 4), 7.39–7.42. (8H, m, Phenyl–*H* × 8), 7.49 (4H, s, Ar–*H* × 4), 7.56 (2H, s, N*H* × 2), 8.29 (2H, s, N*H* × 2), 8.69 (2H, s, N*H* × 2) ppm. ^{13}C NMR (100 MHz, CDCl$_3$–DMSO, 10:1): δ = 30.9 (CH$_3$), 31.3 (CH$_3$), 34.4 (C(CH$_3$)$_3$), 34.5 (C(CH$_3$)$_3$), 66.1 (OCH$_2$), 68.5 (OCH$_2$), 69.9 (OCH$_2$), 71.6 (OCH$_2$), 73.5 (OCH$_2$), 118.1 (ArC), 122.9 (ArC), 123.9 (CF$_3$), 124.2 (CF$_3$), 125.6 (ArC), 125.8 (ArC), 125.9 (ArC), 126.4 (ArC), 126.9 (ArC), 127.0 (ArC), 128.2 (ArC), 147.4 (ArC), 148.4 (ArC), 154.6 (ArC), 154.8 (CO), 155.5 (ArC) and 167.5 (CO) ppm. FABMS: *m/z*: 1397.44 (M$^+$). C$_{68}$H$_{78}$F$_6$N$_6$O$_{11}$S$_4$ (1397.63): calcd C 58.44, H 5.63, N 6.01. Found: C 58.62, H 5.53, N 6.13.

Synthesis of receptor 4$_d$

To compound **3** (150 mg, 0.147 mmol) in THF (10 mL), was added 3,5–bis(trifluoromethyl)phenyl isocyanate (82 mg, 0.320 mmol) and the mixture was stirred for at room temperature for 24 h under argon. The resulting precipitate was collected by filtration, washed with EtOH to give receptor **4$_d$** as a white solid. Recrystallization from CHCl$_3$–CH$_3$CN (1:1) gave receptor **4$_d$** (187 mg, 83 %) as white solid. M.p. 208–210 °C. IR: υ_{max} (KBr)/cm^{-1}: 3315, 2963, 1677, 1577, 1443, 1215, 1136,

1092, 1019 and 880. ^{1}H NMR (300 MHz, CDCl$_3$–DMSO, 10:1): δ = 1.32 (18H, s, *t*Bu × 2), 1.39 (18H, s, *t*Bu × 2), 3.01 (4H, t, *J* = 9.1 Hz, O*CH$_2$* × 2), 3.40 (4H, br, O*CH$_2$* × 2), 3.64 (4H, s, O*CH$_2$* × 2), 3.89 (4H, t, *J* = 9.1 Hz, O*CH$_2$* × 2), 4.63 (4H, s, O*CH$_2$*CO × 2), 7.28 (2H, s, Phenyl–*H* × 2), 7.38 (4H, s, Ar–*H* × 4), 7.42 (4H, s, Phenyl–*H* × 4), 7.49 (4H, s, Ar–*H* × 4), 7.82 (2H, s, N*H* × 2), 8.49 (2H, s, N*H* × 2), 9.05 (2H, s, N*H* × 2) ppm. ^{13}C NMR (100 MHz, CDCl$_3$–DMSO, 10:1): δ = 30.8 (CH$_3$), 31.2 (CH$_3$), 34.3 (*C*(CH$_3$)$_3$), 34.4 (*C*(CH$_3$)$_3$), 65.8 (OCH$_2$), 67.9 (OCH$_2$), 69.7 (OCH$_2$), 71.4 (OCH$_2$), 73.4 (OCH$_2$), 115.3 (ArC), 117.7 (ArC), 121.6 (ArC), 124.3 (CF$_3$), 126.1 (ArC), 126.7 (ArC), 127.0 (ArC), 127.9 (ArC), 131.7 (ArC), 140.4 (ArC), 147.4 (ArC), 148.4 (ArC), 154.1 (ArC), 154.5 (ArC), 155.4 (CO), 155.5 (ArC) and 167.4 (CO) ppm. FABMS: *m/z*: 1533.48 (M$^+$). C$_{70}$H$_{76}$F$_{12}$N$_6$O$_{11}$S$_4$ (1533.63): calcd C 54.82, H 4.99, N 5.48. Found: C 54.63, H 5.05, N 5.35.

Synthesis of receptor 4$_e$

To compound **3** (150mg, 0.147 mmol) in THF (10 mL), was added *p*-nitrophenyl isocyanate (53 mg, 0.320 mmol) and the mixture was stirred for at room temperature for 24 h under argon. The resulting precipitate was collected by filtration, washed with EtOH to give receptor **4$_e$** as a pale yellow solid. Recrystallization from CHCl$_3$–CH$_3$CN (3:1) gave receptor **4$_e$** (165 mg, 83%) as pale yellow solid. M.p. 212–215 °C. IR: υ$_{max}$ (KBr)/cm^{-1}: 3257, 2957, 1682, 1555, 1512, 1445, 1415, 1266, 1150, 1091 and 850. ^{1}H NMR (300 MHz, CDCl$_3$–DMSO, 10:1): δ = 1.27 (18H, s, *t*Bu × 2), 1.39 (18H, s, *t*Bu × 2), 2.97 (4H, t, *J* = 9.1 Hz, O*CH$_2$* × 2), 3.40 (4H, br, O*CH$_2$* × 2), 3.63 (4H, s, O*CH$_2$* × 2), 3.85 (4H, t, *J* = 9.1 Hz, O*CH$_2$* × 2), 4.58 (4H, s, O*CH$_2$*CO × 2) 7.40 (4H, s, Ar–*H* × 4), 8.57 (4H, s, Ar–*H* × 4), 7.58 (4H, d, *J* = 9.3 Hz, Phenyl–*H* × 4), 7.66 (2H, s, N*H* × 2), 8.06 (4H, d, *J* = 9.3 Hz, Phenyl–*H* × 4), 8.40 (2H, s, N*H* × 2), 9.08 (2H, s, N*H* × 2) ppm. ^{13}C NMR (100 MHz, CDCl$_3$–DMSO, 10:1): δ = 30.9 (CH$_3$), 31.3 (CH$_3$), 34.4 (*C*(CH$_3$)$_3$), 34.5 (*C*(CH$_3$)$_3$), 66.2 (OCH$_2$), 69.0 (OCH$_2$), 69.9 (OCH$_2$), 71.7 (OCH$_2$), 73.6 (OCH$_2$), 118.1 (ArC), 124.9 (ArC), 126.2 (ArC), 127.1 (ArC), 127.7 (ArC), 128.0 (ArC), 128.4 (ArC), 142.6 (ArC), 144.5 (ArC), 147.5 (ArC), 147.3 (ArC), 147.9 (ArC), 148.2 (ArC), 154.0 (ArC), 154.2 (CO), 155.7 (ArC) and 168.5 (CO) ppm. FABMS: *m/z*: 1351.57 (M$^+$). C$_{66}$H$_{78}$N$_8$O$_{15}$S$_4$ (1351.63): calcd C 58.65, H 5.82, N 8.29. Found: C 58.81, H 5.75, N 8.12.

Determination of the Association Constants

The association constants were determined by using ^{1}H NMR spectroscopic titration experiments in a constant concentration of host receptor (4.0 × 10^{-3} M) and varying the guest concentration (0–8.0 × 10^{-3} M). The ^{1}H NMR chemical shift of the urea protons (NH) signal was used as a probe. The association constant (K_a) for the complexes of receptor **4$_{a–e}$** were calculated by nonlinear curve-fitting analysis of the observed chemical shifts of the NH protons according to the literature procedure.[14]

^{1}H NMR Titration Experiments

A solution of Bu$_4$NX (X = F, Cl, Br, I, AcO, PhCOO, H$_2$PO$_4$) in CD$_3$CN (4.0 × 10^{-3} M) was added to a CDCl$_3$ solution of receptor **4$_{a–e}$** in the absence or presence of KSO$_3$CF$_3$ in an NMR tube. ^{1}H NMR spectra were recorded after addition of the reactants and the temperature of the NMR probe was kept constant at 27 °C. The ^{1}H NMR spectroscopic data of representative complexes are given below:

receptor **4$_a$**⊃Cl$^-$: ^{1}H NMR (300 MHz, CHCl$_3$–DMSO–CH$_3$CN, 10:1:1, v/v): δ = 2.97 (4H, br, O*CH$_2$* × 2), 3.40 (4H, br, O*CH$_2$* × 2), 3.63 (4H, br, O*CH$_2$* × 2), 3.85 (4H, br, O*CH$_2$* × 2), 4.59 (4H, s, O*CH$_2$*O × 2), 7.89 (2H, br, N*H$_c$* × 2), 8.10 (2H, br, N*H$_b$* × 2) and 8.95 (2H, br, N*H$_a$* × 2) ppm.

receptor **4$_b$**⊃Cl$^-$: ^{1}H NMR (300 MHz, CHCl$_3$–DMSO–CH$_3$CN, 10:1:1, v/v): δ = 2.97 (4H, br, O*CH$_2$* × 2), 3.40 (4H, br, O*CH$_2$* × 2), 3.63 (4H, br, O*CH$_2$* × 2), 3.85 (4H, br, O*CH$_2$* × 2), 4.68 (4H, s, O*CH$_2$*O × 2), 7.80 (2H, br, N*H$_c$* × 2), 8.09 (2H, br, N*H$_b$* × 2) and 8.63 (2H, br, N*H$_a$* × 2) ppm.

receptor **4$_c$**⊃Cl$^-$: ^{1}H NMR (300 MHz, CHCl$_3$–DMSO–CH$_3$CN, 10:1:1, v/v): δ = 2.97 (4H, br, O*CH$_2$* × 2), 3.40 (4H, br, O*CH$_2$* × 2), 3.63 (4H, br, O*CH$_2$* × 2), 3.85 (4H, br, O*CH$_2$* × 2), 4.68 (4H, s, O*CH$_2$*O × 2), 8.01 (2H, br, N*H$_c$* × 2), 8.20 (2H, br, N*H$_b$* × 2) and 9.58 (2H, br, N*H$_a$* × 2) ppm.

receptor **4$_d$**⊃Cl$^-$: ^{1}H NMR (300 MHz, CHCl$_3$–DMSO–CH$_3$CN, 10:1:1, v/v): δ = 3.01 (4H, br, O*CH$_2$* × 2), 3.40 (4H, br, O*CH$_2$* × 2), 3.64 (4H, br, O*CH$_2$* × 2), 3.89 (4H, br, O*CH$_2$* × 2), 4.63 (4H, s, O*CH$_2$*O × 2), 7.94 (2H, br, N*H$_c$* × 2), 8.33 (2H, br, N*H$_b$* × 2) and 9.70 (2H, br, N*H$_a$* × 2) ppm.

receptor **4$_e$**⊃Cl$^-$: ^{1}H NMR (300 MHz, CHCl$_3$–DMSO–CH$_3$CN, 10:1:1, v/v): δ = 2.97 (4H, br, O*CH$_2$* × 2), 3.40 (4H, br, O*CH$_2$* × 2), 3.63 (4H, br, O*CH$_2$* × 2), 3.85 (4H, br, O*CH$_2$* × 2), 4.60 (4H, s, O*CH$_2$*O × 2), 8.10 (2H, br, N*H$_c$* × 2), 8.18 (2H, br, N*H$_b$* × 2) and 10.8 (2H, br, N*H$_a$* × 2) ppm.

receptor **4$_e$**⊃K$^+$: ^{1}H NMR (300 MHz, CHCl$_3$–DMSO–CH$_3$CN, 10:1:1, v/v): δ = 3.11 (4H, br, O*CH$_2$* × 2), 3.36–3.58. (4H, m, O*CH$_2$* × 2), 3.64–3.90. (4H, m, O*CH$_2$* × 2), 4.08 (4H, br, O*CH$_2$* × 2), 4.30–4.61. (4H, m, O*CH$_2$*O × 2), 8.10 (2H, s, NH$_c$ × 2), 8.95 (2H, broad s, NH$_b$ × 2) and 9.09 (2H, broad s, NH$_a$ × 2) ppm.

Cl$^-$⊂[receptor **4$_e$**⊃K$^+$]: ^{1}H NMR (300 MHz, CHCl$_3$–DMSO–CH$_3$CN, 10:1:1, v/v): δ = 2.97 (4H, br, O*CH$_2$* × 2), 3.40 (4H, br, O*CH$_2$* × 2), 3.63 (4H, br, O*CH$_2$* × 2), 3.85 (4H, br, O*CH$_2$* × 2), 4.60 (4H, s, O*CH$_2$*O × 2), 8.14 (2H, br, N*H$_c$* × 2), 8.58 (2H, br, N*H$_b$* × 2) and 10.2 (2H, br, N*H$_a$* × 2) ppm.

receptor **4$_e$**⊃Br$^-$: ^{1}H NMR (300 MHz, CHCl$_3$–DMSO–CH$_3$CN, 10:1:1, v/v): δ = 2.97 (4H, br, O*CH$_2$* × 2), 3.40 (4H, br, O*CH$_2$* × 2), 3.63 (4H, br, O*CH$_2$* × 2), 3.85 (4H, br, O*CH$_2$* × 2), 4.60

(4H, s, OCH_2O × 2), 7.52 (2H, br, NH_c × 2), 8.25 (2H, br, NH_b × 2) and 9.27 (2H, br, NH_a × 2)

Br⁻ ⊏ [receptor **4$_e$** ⊃ K⁺]: ¹H NMR (300 MHz, CHCl₃–DMSO–CH₃CN, 10:1:1, v/v): δ = 3.11 (4H, br, OCH_2 × 2), 3.36–3.58. (4H, m, OCH_2 × 2), 3.64–3.90. (4H, m, OCH_2 × 2), 4.08 (4H, br, OCH_2 × 2), 4.30–4.61. (4H, m, OCH_2O × 2), 7.81 (2H, br, NH_c × 2), 8.10 (2H, br, NH_b × 2) and 9.51 (2H, br, NH_a × 2)

Crystallographic Analysis of receptor 4$_b$ and 4$_e$

Crystal data for **4$_b$**: C₆₈H₈₄N₆O₁₁S₄·½(H₂O)·1½(CHCl₃), M_r = 1477.71. Monoclinic, $P2_1/n$; a = 18.8935 (13), b = 23.9302 (16), c = 33.589 (2) Å; β = 91.5063 (12)°; V = 15181.2 (17) Å³; Z = 8; D_x = 1.293 Mg m⁻³; $F(000)$ = 6224; T = 210(2) K; μ (Mo-K_α) = 0.34 mm⁻¹; λ = 0.71073 Å, crystal size 0.71 × 0.54 × 0.32 mm³. Crystals were colorless blocks. Diffraction data were measured on a Bruker APEX 2 CCD diffractometer equipped with graphite monochromated Mo$_{K\alpha}$ radiation by thin-slice ω-scans.[15] 134900 measured reflections, 31218 independent reflections (R_{int} = 0.049) to θ_{max} = 26.5°; 19539 reflections with I > 2σ(I). The structure was determined by direct methods using the *SHELXS* program and refined by the full-matrix least-squares method, on F^2, in *SHELXL-2013/14*.[16,17] The non-hydrogen atoms were refined with anisotropic thermal parameters. Hydrogen atoms on C were included in idealized positions and their U_{iso} values were set to ride on the U_{eq} values of the parent atoms. H atoms on N were freely refined. At the conclusion of the refinement, wR_2 = 0.173 (all data) and R_1 = 0.056 (observed data), 1903 parameters, $\Delta\rangle_{max}$ = 0.56 eÅ⁻³; 465 restraints, $\Delta\rangle_{min}$ = –0.43 eÅ⁻³. The platon Squeeze procedure was used to model two of the three unique CHCl₃ molecules due to severe disorder.[18] Two-fold disorder was modelled in some *t*Bu groups, in parts of one of the crown ether chains and the other CHCl₃ molecule. H atoms on water molecule O(23) could not be located in difference maps, so were not included in the model.

Crystallographic data (excluding structure factors) for the structure in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication number CCDC 1026081 for **4$_b$**.

Crystal data for **4$_e$**: C₆₆H₇₈N₈O₁₅S₄·½(CHCl₃)·3(MeCN), M_r = 1534.44. Monoclinic, $P2_1/c$; a = 17.7980(10), b = 26.7870(16), c = 32.552(2) Å; β = 96.384(4)°; V = 15423.1(16) Å³; Z = 8; D_x = 1.322 Mg m⁻³; $F(000)$ = 6272; T = 100(2) K; μ (Mo-Kα) = 0.31 mm⁻¹; λ = 0.7749 Å, crystal size 0.25 × 0.25 × 0.02 mm³. Crystals were colorless plates. Diffraction data were measured on a Bruker APEX 2 CCD diffractometer at station 11.3.1 of the ALS using synchrotron radiation by thin-slice ω-scans.[15] 1555885 measured reflections, 50956 independent reflections (R_{int} = 0.052) to θ_{max} = 34.8°; 35702 reflections with I > 2σ(I). Structure solution with SHELXT and refinement as above.[16,17] Hydrogen atoms on C and some N atoms were included in idealized positions and their U_{iso} values were set to ride on the U_{eq} values of the parent atoms. H atoms on the remaining N atoms were freely refined. At the conclusion of the refinement,

wR_2 = 0.294 (all data) and R_1 = 0.086 (observed data), 2055 parameters, $\Delta\rangle_{max}$ = 2.44 eÅ⁻³; 656 restraints, $\Delta\rangle_{min}$ = –1.86 eÅ⁻³. The platon Squeeze procedure was used to model four of the six unique MeCN molecules due to severe disorder.[18] Two-fold disorder was modelled in some *t*Bu groups and in parts of one the crown ether chains and one HN*p*-C₆H₄NO₂ group.

Crystallographic data (excluding structure factors) for the structure in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication number CCDC 1026090 for **4$_e$**.

Notes and references

[a] Department of Applied Chemistry, Faculty of Science and Engineering, Saga University, Honjo-machi 1, Saga 840-8502 Japan, E-mail: yamatot@cc.saga-u.ac.jp
[b] Department Key Laboratory of Macrocyclic and Supramolecular Chemistry of Guizhou Province, Guizhou University, Guiyang, Guizhou, 550025, China.
[c] Chemistry Department, Loughborough University, Loughborough LE11 3TU, UK.
[d] Department of Chemistry, The University of Hull, HU6 7RX, UK.
[e] ALS, Berkeley Lab, 1 Cyclotron Road, Bereleley, CA 94720, USA.

† Electronic Supplementary Information (ESI) available: Details of the ¹H/¹³C NMR spectra, ¹H NMR spectroscopic and UV-vis titration experimental data, the Bensei–Hilderbrand plot and Job's plot, See DOI: 10.1039/b000000x/

1 (*a*) C. D. Gutsche, *Calixarenes, An Introduction,* Royal Society of Chemistry*:* Cambridge, UK, 2008; (*b*) A. Ikeda and S. Shinkai, *Chem. Rev.,* 1997, **97**, 1713–1734; (*c*) D. Coquière, S. Le Gac, U. Darbost, O. Sénèque, I. Jabin and O. Reinaud, *Org. Biomol. Chem.,* 2009, **7**, 2485–2500; (*d*) K. Cottet, P. M. Marcos and P. J Cragg, *Beilstein, J. Org. Chem.* 2012, **8**, 201–226; (*e*) L. Mutihac, J. H. Lee, J. S. Kim and J. Vicens, *Chem. Soc. Rev.*, 2011, **40**, 2777–2796; (*f*) L. Baldini, A. Casnati, F. Sansone and R. Ungaro, Chem. Soc. Rev., 2007, **36**, 254–266; (*g*) J. S. Kim and D. T. Quang, *Chem. Rev.*, 2007, **107**, 3780–3799; (*h*) R. Joseph and C. P. Rao, *Chem. Rev.*, 2011, **111**, 4658–4702; (*i*) C. Capici, Y. Cohen, A. D'Urso, G. Gattuso, A. Notti, A. Pappalardo, S. Pappalardo, M. F. Parisi, R. Purrello, S.Slovak and V. Villari, *Angew. Chem., Int. Ed.*, 2011, **50**, 12162–12167; (*j*) C.

RSC Advances Accepted Manuscript

Talotta, C. Gaeta1, Z. Qi, C. A. Schalley and P. Neri, *Angew. Chem., Int. Ed*., 2013, **52**, 7437–7441; (*k*) M.-X. Wang, *Acc. Chem. Res.,* 2012*,* **45***,* 182–195.

2 (*a*) H. Kumagi, M. Hasegawa, S. Miyanari, Y. Sugawa, Y. Sato, T. Hori, S. Ueda, H. Kamiyama and S. Miyano, *Tetrahedron Lett.,* 1997, **38**, 3971–3972.

3 (*a*) P. Lhoták, *Eur. J. Org. Chem.*, 2004, 1675–1692; (*b*) N. Morohashi, F. Narumi, N. Iki, T. Hattori and S. Miyano, *Chem. Rev.,* 2006, **106**, 5291–5316.

4 (*a*) P. D. Beer and P. A. Gale, *Angew. Chem. Int. Ed.,* **2001**, 40, 486–516; (*b*) T. Nabeshima, T. Saiki and S. Kumitomo, *Org. Lett*., 2002, **4**, 3207–3209; (*c*) T. Nabeshima, Y. Yoshihira, T. Saiki, S. Akine and E. Horn, *J. Am. Chem. Soc.,* 2003, **125**, 28–29; (*d*) A. Y. Zhukov, T. A. Fink, I. I. Stoikov and I. S. Antipin, *Russ. Chem. Bull., Int. Ed.,* 2009, **58**, 1007–1014; (*e*) K. Mohr, J. Schmitz, R. Schrage, C. Trnkle and U. Holzgrabe, *Angew. Chem. Int. Ed*., 2013, **52**, 508–516; (*f*) R. Nussinov and C.-J. Tsai, *Cell,* 2013, **153**, 293–305.

5 (*a*) J.–Y Kwon, Y.–J Jang, S.–K Kim, K.–H Lee, J.–S Kim and J. Yoon, *J. Org. Chem.,* 2004, **69**, 5155–5157; (*b*) D. Amilan Jose, D. K. Kumar, B. Ganguly and A. Das, *Org. Lett.*, 2004, **6**, 3445–3448; (*c*) J.–Y. Lee, E.–J Cho, S. Mukamel and K.–C. Nam, *J. Org. Chem.*, 2004, **69**, 943–950; (*d*) D. Esteban-Go´mez, L. Fabbrizzi and M. Licchelli, *J. Org. Chem.,* 2005, **70**, 5717–5720; (*e*) V. Thiagarajan, P. Ramamurthy, D. Thirumalai and V. T. Ramakrishnan, *Org. Lett.*, 2005, **7**, 657–660; (*f*) H. Lu, W. Xu, D. Zhang, C. Chen and D. Zhu, *Org. Lett.*, 2005, **7**, 4629–4632; (*g*) F. M. Pfeffer, T. Gunnlaugsson, P. Jensen and P. E. Kruger, *Org. Lett.*, 2005, **7**, 5357–5360; (*h*) L. Fang, W.–H. Chan, Y.–B He, D. W.–J. Kwong and A. W.–M. Lee, *J. Org. Chem.,* 2005, **70**, 7640–7646; (*i*) T. Gunnlaugsson, P. E. Kruger, P. Jensen, J. Tierney, H. D. Paduka Ali and G. M. Hussey, *J. Org. Chem.*, 2005, **70**, 10875–10878; (*j*) A. Dahan, T. Ashkenazi, V. Kuznetsov, S. Makievski, E. Drug, L. Fadeev, M. Bramson, S. Schokoroy, E. Rozenshine–Kemelmakher and M. Gozin, *J. Org. Chem.,* 2007, **72**, 2289–2296; (*k*) S. Saha, A. Ghosh , P. Mahato , S. Mishra , S. K. Mishra, E. Suresh , S. Das and A. Das, *Org. Lett.*, 2010, **12**, 3406–3409.

6 (a) J. L. Sessler, P. A. Gale and W. S. Cho, Anion Receptor Chemistry; Royal Society of Chemistry: Cambridge, U.K., 2006; (b) P. D. Beer, P.A. Gale, *Angew. Chem., Int. Ed*., 2001, **40**, 486–516.

7 (a) J. F. Zhang, Y. Zhou, J. Yoon and J. S. Kim, *Chem. Soc. Rev*., 2011, **40**, 3416–3429; (b) C. Lodeiro, J. L. Capelo, J. C. Mejuto, E. Oliveira, H. M. Santos, B. Pedras and C. Nuñez, *Chem. Soc. Rev*., 2010, **39**, 2948–2976; (c) L. E. Santos-Figueroa, M. E. Moragues, E. Climent, A. Agostini, R. Martínez-Máñez and F. Sancenón, *Chem. Soc. Rev*., 2013, **42**, 3489–613.

8 (*a*) R. M. F. Batista, E. Oliveira, S. P. G. Costa, C. Lodeiro and M. M. M. Raposo, *Org. Lett.* 2007, **9**, 3201–3204; (*b*) F. Zapata, A. Caballero, A. Espinosa, A. Tárraga, and P. Molina, *Org. Lett.*, 2008, **10**, 41–44; (*c*) R. D. Rasberry, M. D. Smith and K. D. Shimizu, *Org. Lett.* 2008, **10**, 2889–2892; (*d*) C. Pérez-Casas and A. K. Yatsimirsky, *J. Org.*

Chem., 2008, **73**, 2275–2284; (*e*) J. P. Clare, A. Statnikov, V. Lynch, A. L. Sargent and J. W. Sibert, *J. Org. Chem.*, 2009, **74**, 6637–6646; (*f*) Q.–S Lu, L. Dong, J. Zhang, J. Li, L. Jiang, Y. Huang, S. Qin, C.–W. Hu and X.–Q. Yu, *Org. Lett.*, 2009, **11**, 669–672; (*g*) S. Goswami, D. Sen and N. K. Das, *Org. Lett.*, 2010, **12**, 856–859; (*h*) A. Aldrey, C. Núñez, V. García, R. Bastida, C. Lodeiro, A. Macías, *Tetrahedron*, 2010, **66**, 9223–9230; (*i*) P. Dydio, T. Zieliński and J. Jurczak, *Org. Lett.*, 2010, **12**, 1076–1078; (*j*) V. K. Bhardwaj, S. Sharma, N. Singh, M. S. Hundal and G. Hundal, *Supramol. Chem.*, 2011, **23**, 790–800; (*k*) G.–W. Lee, N.–K. Kim and K.–S. Jeong, *Org. Lett.*, 2011, **13**, 3024–3027; (*l*) H. M. Chawla, S. N. Sahu, R. Shrivastava, S. Kumar, *Tetrahedron Lett.*, 2012, **53**, 2244–2247; (*m*) S. Goswami, A. Manna, S. Paul, K. Aich, A. K. Das and S. Chakraborty, *Tetrahedron Lett.*, 2013, **54**, 1785–1789; (*n*) K. Pandurangan, J. A. Kitchen and T. Gunnlaugsson, *Tetrahedron Lett.*, 2013, **54**, 2770–2775; (*o*) S. Areti, J. K. Khedkar, R. Chilukula and C. P. Rao, *Tetrahedron Lett.*, 2013, **54**, 5629–5634; (*p*) C. Jin, M. Zhang, C. Deng, Y. Guan, J. Gong, D. Zhu, Y. Pan, J. Jiang and L. Wang, *Tetrahedron Lett.*, 2013, **54**, 796–801.

9 (*a*) K. Lang, P. Cuřínová, M. Dudič, P. Prošcová, I. Stibor, V. Šťastný and P. Lhoták, *Tetrahedron Lett.*, 2005, **46**, 4469–4472; (*b*) P. Lhoták, J. Svoboda and I. Stibor, *Tetrahedron Lett.*, 2006, **62**, 1253–1257; (*c*) J. Kroupa, I. Stibor, M. Pojarová, M. Tkadlecová and P. Lhoták, *Tetrahedron*, 2008, **64**, 10075–10079; (*d*) O. Kundrat, H. Dvorakova, I. Cisarova, M. Pojarova and P. Lhoták, *Org. Lett.*, 2009, **11**, 4188–4191; (*e*) O. Kundrat, I. Cisarova, S. Böhm, M. Pojarova and P. Lhoták, *J. Org. Chem.*, 2009, **74**, 4592–4596; (*f*) O. Kundrat, H. Dvorakova, V. Eigner and P. Lhoták, *J. Org. Chem.*, 2010, **75**, 407–411; (*g*) O. Kundrat, J. Kroupa, S. Böhm, J. Budka, V. Eigner and P. Lhoták, *J. Org. Chem.*, 2010, **75**, 8372–8375; (*h*) O. Kundrát, V. Eigner, P. Cuřínová, J. Kroupa and P. Lhoták, *Tetrahedron*, 2011, **67**, 8367–8372; (*i*) O. Kundrat, V. Eigner, H. Dvorakova, and P. Lhoták, *Org. Lett.*, 2011, **13**, 4032–4035; (*j*) P. Slavik, M. Dudic, K. Flidrova, J. Sykora, I. Cisarova, M. Pojarova and P. Lhoták, *Org. Lett.*, 2012, **14**, 3628–3631; (*k*) O. Kundrat, H. Dvorakova, S. Böhm, V. Eigner and P. Lhoták, *J. Org. Chem.*, 2012, **77**, 2272–2278.

10 (*a*) V. Bhalla, M. Kumar, H. Katagiri, T. Hattori and S. Miyano, *Tetrahedron Lett*., 2005, **46**, 121–124; (*b*) V. Bhalla, J. N. Babu, M. Kumar, T. Hattori and S. Miyano, *Tetrahedron Lett.,* 2007, **48**, 1581–1585; (*c*) V. Bhalla, R. Kumar, M. Kumar and A. Dhir, *Tetrahedron*, 2007, **63**, 11153–11159; (*d*) A. Dhir, V. Bhalla and M. Kumar, *Org. Lett*., 2008, **10**, 4891–4894; (*e*) R. Kumar, V. Bhalla and M. Kumar, *Tetrahedron*, 2008, **64**, 8095–8101; (*f*) R. K. Mahajan, R. Kaur, V. Bhalla, M. Kumar, T. Hattori and S. Miyano, *Sens. Actuators B*, 2008, **130**, 290–294; (*g*) J. N. Babu, V. Bhalla, M. Kumar, R. K. Mahajan and R. K. Puri, *Tetrahedron Lett.*, 2008, **49**, 2772–2775; (*h*) M. Kumar, A. Dhir and V. Bhalla, *Org. Lett*., 2009, **11**, 2567–2570; (*i*) M. Kumar, R. Kumar and V. Bhalla, *Tetrahedron,* 2009, **65**, 4340–4344 (*j*) M. Kumar, A. Dhir and V. Bhalla; *Org. Lett.,* 2009, **11**,

2567–2570; (*k*) M. Kumar, R. Kumar and V. Bhalla, *Tetrahedron Lett*., 2010, **51**, 5559–5562; (*l*) M. Kumar, R. Kumar and V. Bhalla, *Org. Lett.*, 2011, **13**, 366–369; (*m*) M. Kumar, R. Kumar and V. Bhalla, *Org. Bio. Chem.*, **2011**, 9, 8237–8245; (*n*) M. Kumar, R. Kumar and V. Bhalla, *Org. Lett.*, 2011, **13**, 366–369; (*o*) M. Kumar, R. Kumar and V. Bhalla, *Tetrahedron Lett.*, 2013, **54**, 1524–1527.

11   (*a*) C. Perez-Casas and T. Yamato, *J. Incl. Phenom. Macrocyclic Chem.,* 2005, **53**, 1–8; (*b*) T. Yamato, C. Perez-Casas, H. Yamamoto, M. R. J. Elsegood, S. H. Dale and C. Redshaw, *J. Incl. Phenom. Macrocyclic Chem.,* 2006, **54**, 261–269; (c) C. Perez-Casas, S. Rahman, N. Begum, Z. Xi and T. Yamato, *J. Incl. Phenom. Macrocyclic Chem.*, 2008, **60**, 173–185; (*d*) X.–L. Ni, X. Zeng, C. Redshaw and T. Yamato, *J. Org. Chem.*, 2011, **76**, 3358–3370; (e) X.-L. Ni, X. Zeng, C. Redshaw and T. Yamato, *Tetrahedron*, 2011, **67**, 3248–3253; (*h*) X.–L. Ni, J. Tahara, S. Rahman, X. Zeng, D. L. Hughes, C. Redshaw and T. Yamato, *Chem. Asian. J.*, 2012, **7**, 519–527; (*i*) X.–L. Ni, H. Cong, A. Yoshizawa, S. Rahman, H. Tomiyasu, U. Rayhan, X. Zeng and T. Yamato, *J. Mol. Struct.*, 2013, **1046**, 110–115.

12   F. W. B. van Leewen, H. Beijleveld, H. Kooijman, A. L. Spek, W. Verboom and D. N. Reinhoudt, *J. Org. Chem.*, 2004, **69**, 3928–3936.

13   N. Iki, N. Morohashi, F. Narumi, T. Fujimoto, T. Suzuki and S. Miyano, *Tetrahedron. Lett.*, 1999, **40**, 7337–7341.

14   H. A. Benesi and J. H. Hildebrand, *J. Am. Chem. Soc.*, 1949, **71**, 2703–2707.

15   APEX 2 and SAINT, 2011, software for CCD diffractometers. Bruker AXS Inc., Madison, USA.

16   G.M. Sheldrick, *Acta Crystallogr.* **2008**, A64, 112–122.

17   G.M. Sheldrick, *Acta Crystallogr.* **2015**, A71, 3–8.

18   A.L. Spek, A.L., *Acta Crystallogr.* **1990**, A46, C34.

RSC Advances Accepted Manuscript